APN logo

Aspen Pharmacare Holdings Limited Stock Price

JSE:APN Community·R63.0b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 57 Fair Values set on narratives written by author

APN Share Price Performance

R141.94
27.66 (24.20%)
R120.60
Fair Value
R141.94
27.66 (24.20%)
17.7% overvalued intrinsic discount
R120.60
Fair Value
Price R141.94
AnalystConsensusTarget R120.60

APN Community Narratives

·
Fair Value R120.6 17.7% overvalued intrinsic discount

Commercial Pharma And GLP-1 Expansion Will Empower Future Progress

0users have liked this narrative
0users have commented on this narrative
29users have followed this narrative
R120.6
17.7% overvalued intrinsic discount
Profit Margin
13.23%
Future PE
12.59x
Price in 2028
R191.73

Trending Discussion

No trending discussion available.

Updated Narratives

APN logo

Commercial Pharma And GLP-1 Expansion Will Empower Future Progress

Fair Value: R120.6 17.7% overvalued intrinsic discount
29 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and undervalued.

0 Risks
3 Rewards

Aspen Pharmacare Holdings Limited Key Details

R42.6b

Revenue

R24.3b

Cost of Revenue

R18.3b

Gross Profit

R20.1b

Other Expenses

-R1.8b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Sep 02, 2026
-4.07
42.99%
-4.24%
40.6%
View Full Analysis

About APN

Founded
1850
Employees
9343
CEO
Stephen Saad
WebsiteView website
www.aspenpharma.com

Aspen Pharmacare Holdings Limited, together with its subsidiaries, operates as a specialty and branded pharmaceutical company in Africa, the Middle East, Europe, CIS, Australasia, Asia, and the Americas. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers sterile products in injectable form primarily administered in hospitals and prescribed and administered by physicians or in a retail pharmacy environment for therapeutic areas, such as anesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Sandostatin, Sustanon, and Xylocaine brands. It also provides over-the-counter topical products through retail pharmacy and fast-moving consumer goods sectors under the EMLA, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for therapeutic areas, including anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Meticorten brands. In addition, the company manufactures active pharmaceutical ingredients; finished dose form products manufactured for third parties; and heparin-based API to third parties. Further, it exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.

Recent APN News & Updates

Recent updates

No updates

Aspen Pharmacare Holdings Limited Competitors